Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794871 | 0.87 | ALOX15 (0.50) | ALOX15ALDH1A1BCL9CTNNB1MAPT | |
| SCHEMBL8383426 | 0.87 | ALOX15 (0.50) | ALOX15ALDH1A1BCL9CTNNB1MAPT | |
| SCHEMBL6742480 | 0.85 | ALOX15 (0.48) | ALOX15ALDH1A1BCL9CTNNB1MAPT | |
| SCHEMBL9521629 | 0.84 | ALDH1A1 (0.47) | ALDH1A1MAPTALPGLMNAGAA | |
| SCHEMBL10804019 | 0.84 | ALOX15 (0.47) | ALOX15ALDH1A1BCL9CTNNB1MAPT | |
| SCHEMBL3617307 | 0.82 | ALOX15 (0.68) | ALOX15ALDH1A1MAPTLMNAGAA | |
| SCHEMBL27768435 | 0.81 | BCL9 (0.62) | ALOX15ALDH1A1BCL9CTNNB1MAPT | |
| SCHEMBL6990630 | 0.81 | LMNA (0.58) | ALDH1A1MAPTALPGLMNAGAA | |
| SCHEMBL2976618 | 0.81 | GAA (0.60) | ALDH1A1LMNAGAAHTTMEN1 | |
| SCHEMBL2976612 | 0.81 | GAA (0.60) | ALDH1A1LMNAGAAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ALOX15 622/4885ALDH1A1 3196/4885BCL9 1071/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | ALOX15 598/4885ALDH1A1 3103/4885BCL9 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.